Author Affiliations: Health Outcomes and Pharmacoeconomics (Drs Mahadevia and Masaquel) and Medical Affairs (Dr Makari), MedImmune LLC, Gaithersburg, Maryland.
Hampp and colleagues1 present an economic analysis of palivizumab prophylaxis during the 2004-2005 respiratory syncytial virus (RSV) season in Florida using Medicaid claims data and assert that palivizumab prophylaxis is not cost-effective compared with no prophylaxis. Several important variables were not considered, which limits the scope of the investigators' conclusions. In addition, their analysis seemed to deviate from guidelines established by the US Panel on Cost-effectiveness in Health and Medicine.2
Mahadevia PJ, Makari D, Masaquel A. Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid. Arch Pediatr Adolesc Med. 2012;166(10):968-970. doi:10.1001/archpediatrics.2012.1591